Liraglutide plus insulin - Diabetes Mellitus
You are here : Home > Formulary Search > Liraglutide plus insulin - Diabetes Mellitus
I agree that in using this database I understand that this platform only provides guidance on local prescribing policy and that all prescribing decisions are ultimately the responsibility of the clinician.
Status 1
Amber
Formulations :
- Not Specified
Formulary Status :
Associated Icons :
Restrictions / Comments :
Documentation
PAD Profile
ChemicalSubstance :
Liraglutide plus insulin
Indication :
Diabetes Mellitus
Group Name :
Keywords :
GLP-1s, GLP1s, GLP 1s, glucagon like peptide-1
Brand Names Include :
Victoza
Important Information :
Latest Additions Date From :
Latest Additions Date To :
Guidelines :
Supporting Documents :
2
Other Indications
Below are listed other indications that Liraglutide plus insulin is used to treat.
- No records returned.
Other Drugs
Below are listed other drugs that are used to treat Diabetes Mellitus.
- Acarbose
- Alogliptin
- Alogliptin/metformin
- Biphasic Insulin Aspart - Novmix 30
- Biphasic Isophane Insulin - Humulin M3
- Biphasic Lispro Insulin - Humalog Mix 25
- Biphasic Lispro Insulin - Humalog Mix 50
- Canagliflozin/metformin
- Dapagliflozin
- Dapagliflozin/metformin
- Diazoxide
- Dulaglutide
- Empagliflozin
- Empagliflozin/metformin
- Ertugliflozin
- Exenatide
- Glibenclamide
- Gliclazide
- Glimepiride
- Glipizide
- Glucose
- Glyxambi (Linagliptin/empagliflozin)
- Insulin Aspart - Fiasp
- Insulin aspart - NovoRapid
- Insulin Aspart - Trurapi
- Insulin degludec
- Insulin degludec with liraglutide
- Insulin detemir
- Insulin glargine - Abasaglar
- Insulin glargine - Lantus
- Insulin glargine - Semglee
- Insulin Glargine - Toujeo
- Insulin glulisine - Apidra
- Insulin Lispro - Admelog
- Insulin Lispro - Humalog
- Insulin Lispro - Lyumjev
- Insulin pump - non-autoimmune causes
- Insulin pump - Type 1 diabetes
- Isophane (neutral insulin) - hypurin porcine 30/70
- Isophane Insulin - Humulin I
- Isophane Insulin - Hypurin Porcine Isophane
- Isophane Insulin - Insulatard
- Linagliptin
- Linagliptin/metformin
- Liraglutide
- Metformin hydrochloride
- Metformin hydrochloride/pioglitazone
- Metformin hydrochloride/sitagliptin
- Metformin hydrochloride/vildagliptin
- Pioglitazone hydrochloride
- Repaglinide
- Saxagliptin
- Saxagliptin/dapagliflozin
- Semaglutide
- Sitagliptin
- Soluble insulin - Hypurin porcine neutral
- Soluble insulin - Actrapid
- Soluble insulin - Humulin S
- Sotagliflozin
- Suliqua (Insulin glargine/lixisenatide)
- Tirzepatide
- Tolbutamide
- Vildagliptin
Committee Recommendations (2)
EMEA and FDA investigations re. GLP-1 drugs being associated with increased risk of pancreatitis and precancerous cellular changes. A letter for all prescribers is attached for information
The Surrey Area Prescribing Committee recommends the concomitant use of GLP-1 with insulin therapy for a defined cohort of patients. Please see the policy statement for further information. The combination of GLP-1 in combination with Insulin is not currently licensed. A shared care document has been developed - see below